ATE200423T1 - Verwendung von 1-(2-naphtylethyl)-4-(3- trifluoromethylphenyl)-1,2,3,6-tetrahydropyridi zur herstellung eines medikaments zur behandlung der amyotrophen lateralsklerode - Google Patents

Verwendung von 1-(2-naphtylethyl)-4-(3- trifluoromethylphenyl)-1,2,3,6-tetrahydropyridi zur herstellung eines medikaments zur behandlung der amyotrophen lateralsklerode

Info

Publication number
ATE200423T1
ATE200423T1 AT96934975T AT96934975T ATE200423T1 AT E200423 T1 ATE200423 T1 AT E200423T1 AT 96934975 T AT96934975 T AT 96934975T AT 96934975 T AT96934975 T AT 96934975T AT E200423 T1 ATE200423 T1 AT E200423T1
Authority
AT
Austria
Prior art keywords
trifluoromethylphenyl
treatment
pct
amyotrophic lateral
sclerode
Prior art date
Application number
AT96934975T
Other languages
English (en)
Inventor
Patrice Douillet
Jacqueline Fournier
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9512635A external-priority patent/FR2740343B1/fr
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of ATE200423T1 publication Critical patent/ATE200423T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
AT96934975T 1995-10-26 1996-10-25 Verwendung von 1-(2-naphtylethyl)-4-(3- trifluoromethylphenyl)-1,2,3,6-tetrahydropyridi zur herstellung eines medikaments zur behandlung der amyotrophen lateralsklerode ATE200423T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9512635A FR2740343B1 (fr) 1995-10-26 1995-10-26 Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
FR9607336 1996-06-13
PCT/FR1996/001674 WO1997015304A1 (fr) 1995-10-26 1996-10-25 Utilisation de la 1-(2-napht-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique

Publications (1)

Publication Number Publication Date
ATE200423T1 true ATE200423T1 (de) 2001-04-15

Family

ID=26232287

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96934975T ATE200423T1 (de) 1995-10-26 1996-10-25 Verwendung von 1-(2-naphtylethyl)-4-(3- trifluoromethylphenyl)-1,2,3,6-tetrahydropyridi zur herstellung eines medikaments zur behandlung der amyotrophen lateralsklerode

Country Status (27)

Country Link
US (1) US6043251A (de)
EP (1) EP0866704B1 (de)
JP (1) JP3468526B2 (de)
KR (1) KR100472793B1 (de)
CN (1) CN1104241C (de)
AT (1) ATE200423T1 (de)
AU (1) AU719342B2 (de)
BR (1) BR9611124A (de)
CA (1) CA2235747C (de)
CY (1) CY2279B1 (de)
CZ (1) CZ293360B6 (de)
DE (1) DE69612510T2 (de)
DK (1) DK0866704T3 (de)
EE (1) EE04177B1 (de)
ES (1) ES2159362T3 (de)
GR (1) GR3036027T3 (de)
HU (1) HU222039B1 (de)
IL (1) IL124091A (de)
IS (1) IS1961B (de)
NO (1) NO316256B1 (de)
NZ (1) NZ320355A (de)
PT (1) PT866704E (de)
SI (1) SI0866704T1 (de)
SK (1) SK284099B6 (de)
TR (1) TR199800717T2 (de)
UA (1) UA57004C2 (de)
WO (1) WO1997015304A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2782008B1 (fr) * 1998-08-07 2003-04-25 Sod Conseils Rech Applic Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
MXPA04005572A (es) * 2001-12-11 2004-12-06 Univ Virginia Uso de pramipexol para tratamiento de esclerosis lateral amiotrofica.
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途
US20080234338A1 (en) * 2005-08-15 2008-09-25 University Of Virginia Patent Foundation Neurorestoration With R(+) Pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
KR20090021169A (ko) 2006-05-16 2009-02-27 크놉 뉴로사이언시스 인코포레이티드 Ｒ(+) 및 ｓ(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CN101715443A (zh) 2007-03-14 2010-05-26 诺普神经科学股份有限公司 手性纯化的取代的苯并噻唑二胺的合成
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES3043076T3 (en) 2013-07-12 2025-11-24 Areteia Therapeutics Inc Treating elevated levels of eosinophils and/or basophils
ES2871556T3 (es) 2013-08-13 2021-10-29 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de la urticaria crónica
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
FR2672213B1 (fr) * 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
FR2672731A1 (fr) * 1991-02-07 1992-08-14 France Telecom Procede d'oxydation localisee enterree d'un substrat de silicium et circuit integre correspondant.
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.

Also Published As

Publication number Publication date
NO316256B1 (no) 2004-01-05
CN1202826A (zh) 1998-12-23
HK1016904A1 (en) 1999-11-12
NO981856L (no) 1998-06-11
GR3036027T3 (en) 2001-09-28
WO1997015304A1 (fr) 1997-05-01
CZ293360B6 (cs) 2004-04-14
UA57004C2 (uk) 2003-06-16
KR19990067057A (ko) 1999-08-16
EP0866704A1 (de) 1998-09-30
HUP9802945A3 (en) 1999-05-28
EE9800132A (et) 1998-10-15
NO981856D0 (no) 1998-04-24
CY2279B1 (en) 2003-07-04
IL124091A (en) 2003-10-31
EE04177B1 (et) 2003-12-15
CZ129698A3 (cs) 1998-07-15
SI0866704T1 (en) 2001-08-31
TR199800717T2 (xx) 1998-09-21
DE69612510D1 (de) 2001-05-17
KR100472793B1 (ko) 2005-06-16
MX9803271A (es) 1998-09-30
JP3468526B2 (ja) 2003-11-17
AU719342B2 (en) 2000-05-04
EP0866704B1 (de) 2001-04-11
DE69612510T2 (de) 2001-11-22
SK284099B6 (sk) 2004-09-08
ES2159362T3 (es) 2001-10-01
HUP9802945A2 (hu) 1999-04-28
HU222039B1 (hu) 2003-03-28
CN1104241C (zh) 2003-04-02
IS4722A (is) 1998-04-21
BR9611124A (pt) 1999-05-11
CA2235747C (en) 2006-01-03
PT866704E (pt) 2001-07-31
AU7308496A (en) 1997-05-15
DK0866704T3 (da) 2001-07-16
IS1961B (is) 2004-11-15
JPH11515012A (ja) 1999-12-21
SK52698A3 (en) 1998-09-09
NZ320355A (en) 2000-03-27
CA2235747A1 (en) 1997-05-01
US6043251A (en) 2000-03-28

Similar Documents

Publication Publication Date Title
DE69612510D1 (de) Verwendung von 1-(2-naphtylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin zur herstellung eines medikaments zur behandlung der amyotrophen lateralsklerode
DE69400435D1 (de) Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson-syndromen
ATE218350T1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
ATE252897T1 (de) Verwendung von p-aminophenolderivaten zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von neurodegenerativen erkrankungen
ATE232094T1 (de) Verwendung eines 5ht2 rezeptor-antagonisten zur behandlung von schlafapnoe
ATE85334T1 (de) Bisphenylalkylpiperazin-derivate, verfahren zur herstellung und arzneimittelzubereitung.
DE69636393D1 (de) Montirelin zur verhinderung der schlafapnoe
DE59607887D1 (de) Verfahren zur herstellung von optisch aktivem 1-(p-methoxybenzyl)-1,2,3,4,5,6,7,8-octahydroisochinolin
DE69430427D1 (de) Verwendung von ropivacaine zur herstellung eines analgetikums mit minimaler motorischer blockade
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
ATE232723T1 (de) Verwendung von allylaminderivaten wie terbinafin zur herstellung eines medikaments zur behandlung von mit einer helicobacter pylori infektion zusammenhängenden erkrankungen
ATE192438T1 (de) Bis-2-aminopyridine, verfahren zu ihrer herstelung und ihre verwendung zur bekämpfung von parasitosen
BR9708922A (pt) Piridil-e pirimidil-piperazinas no tratamento de doenças causadas por substâncias usadas em excesso
ATE182886T1 (de) Neue pyridin- bzw. pyridazinderivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
ATE275548T1 (de) Verfahren zur herstellung eines tetrahydropyridinderivates
DE69625819D1 (de) Die verwendung von ondansetron zur herstellung eines medikamentes zur behandlung von tremor
ATE193445T1 (de) Verwendung des alpha,alpha-diphenylessigsäure-4- (n-methyl-piperidyl)esters als spasmoanalgetikum

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee